L&S Knock-Out VH2 12.12.2024/ DE000LX327V2 /
| 23/05/2024 22:58:11 | Chg.-0.05 | Bid22:58:11 | Ask22:58:11 | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.26EUR | -16.13% | 0.26 Bid Size: - |
0.30 Ask Size: - |
FR.VORWERK GRP SE IN... | 14.00 EUR | 12/12/2024 | Call |
GlobeNewswire
23:23
DOCS INVESTOR NEWS: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Doximity, Inc. Investors to Se...
GlobeNewswire
23:22
HRBR Stockholders: Robbins LLP Reminds HRBR Stockholders of Securities Fraud Class Action Against Ha...
GlobeNewswire
23:21
INTC Stockholders: Robbins LLP Reminds INTC Stockholders of Securities Fraud Class Action Against In...
GlobeNewswire
23:18
Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq
Newsfile Corp
23:15
American Aires Extends Global Expansion by Opening Latest International Fulfillment Center in the UK
GlobeNewswire
23:15
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of ...
GlobeNewswire
23:13
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Onc...
GlobeNewswire
23:10
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-10...
GlobeNewswire
23:09
Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant impr...
GlobeNewswire
23:06
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (A...
GlobeNewswire
23:05
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
GlobeNewswire
23:05
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upco...
GlobeNewswire
23:05
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at A...
GlobeNewswire
23:05
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrat...
GlobeNewswire
23:05
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) ...
GlobeNewswire
23:05
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Adva...
GlobeNewswire
23:05
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study i...
GlobeNewswire
23:04
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combinatio...
GlobeNewswire
23:03
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...
